Document
false0000917520 0000917520 2020-05-18 2020-05-18


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2020

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)

Delaware
0-26224
51-0317849
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

1100 Campus Road
Princeton, NJ 08540
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code: (609) 275-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section12(b) of the Act:
Title of Each Class
Trading Symbol
Name of Exchange on Which Registered
Common Stock, Par Value $.01 Per Share
IART
Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  





Item 5.07. Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of the Company was held on May 13, 2020. The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:

Item No. 1: All of the Board of Directors’ nominees for director were elected to serve until the Company’s 2021 Annual Meeting or until their respective successors are elected and qualified, by the votes set forth below.

Nominees
For
Against
Abstain
Broker Non-Vote
Peter J. Arduini
77,365,713
714,147
66,912
2,666,096
Rhonda G. Ballintyn
77,607,381
464,179
75,212
2,666,096
Keith Bradley
76,779,118
1,291,137
76,517
2,666,096
Stuart M. Essig
76,876,306
1,201,735
68,731
2,666,096
Barbara B. Hill
77,137,039
934,553
75,180
2,666,096
Lloyd W. Howell, Jr.
77,479,591
590,146
77,035
2,666,096
Donald E. Morel, Jr.
77,501,115
568,873
76,784
2,666,096
Raymond G. Murphy
76,401,091
1,668,655
77,098
2,666,096
Christian S. Schade
76,776,244
1,293,206
77,322
2,666,096

Item No. 2: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the 2020 fiscal year, by the votes set forth below.

For
Against
Abstain
Broker Non-Vote
78,275,973
2,482,587
54,308
0

Item No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers, by the votes set forth below.

For
Against
Abstain
Broker Non-Vote
76,578,604
1,507,801
60,367
2,666,096






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
 
 
 
Date: May 18, 2020
By:
 /s/ Carrie Anderson
 
 
Carrie Anderson
 
Title:
Executive Vice President and Chief Financial Officer